Vismodegib (Erivedge)
Vemurafenib (Zelboraf)
Seretide
Mabthera
Apremilast (Otezla)
TEMPUS oncology test suite
Our collection of genomic tests uncover unique insights that empower you to customise treatment for individual patients, throughout their cancer journey.
APIS breast cancer subtyping kit
Receptor tyrosine-protein kinase erbB-2 (HER2), oestrogen receptor (ER), progesterone receptor (PR), and marker of proliferation Ki67 expression plays a key role in breast cancer intrinsic subtype evaluation and guides treatment decisions. The APIS Breast Cancer Subtyping Kit is an RNA-based diagnostic workflow for detecting mRNA expression of standard biomarkers (HER2, ER, PR, Ki67) and a novel proliferative signature from pre-operative core needle biopsy (CNB) or resected formalin-fixed paraffin-embedded (FFPE) breast tumour tissue. The test serves as an alternative method to current standard of care – immunohistochemistry (IHC).